{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,4]],"date-time":"2026-05-04T22:44:04Z","timestamp":1777934644839,"version":"3.51.4"},"reference-count":12,"publisher":"SAGE Publications","issue":"3","license":[{"start":{"date-parts":[[2024,10,21]],"date-time":"2024-10-21T00:00:00Z","timestamp":1729468800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["J Oncol Pharm Pract"],"published-print":{"date-parts":[[2026,4]]},"abstract":"<jats:sec>\n                    <jats:title>Introduction<\/jats:title>\n                    <jats:p>Hypomagnesemia is a common issue in patients with cancer due to magnesium wasting drugs like calcineurin inhibitors, chemotherapy sides effects such as diarrhea, and poor oral intake. Historically, magnesium has been given over prolonged infusions due to concern for rapid elimination of magnesium when large doses are administered. At UW Health, magnesium was given at a rate of 1g\/60\u2005min. A prolonged infusion rate often creates logistical issues including limited IV access, incompatibility concerns and increased chair time. The purpose of this project is to increase the infusion rate of IV magnesium without compromising therapeutic repletion, benefit, and safety.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>The magnesium infusion rate was increased to the following rates: 4g\/60\u2005min, 2g\/30\u2005min, 1g\/15\u2005min. The primary outcome is the grams of IV magnesium replaced per outpatient visit between the pre-intervention (prolonged) and post-intervention (rapid) groups. Secondary outcomes include assessment of differences in chair time between groups and total incidence of critical magnesium lab values.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      There was no statistically significant difference in magnesium requirements per outpatient visit between a prolonged and rapid magnesium infusion rate (2.18g vs 2.15g;\n                      <jats:italic toggle=\"yes\">p<\/jats:italic>\n                      \u2009=\u20090.49). Additionally, there was no difference in number of outpatient visits (3 vs 3;\n                      <jats:italic toggle=\"yes\">p<\/jats:italic>\n                      \u2009=\u20091). The average chair time was decreased by 110\u2005min per outpatient encounter between the prolonged and rapid magnesium infusion rate, which was determined to be clinically and statistically significant.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>This study suggests that there is no difference in magnesium requirements between a rapid or prolonged magnesium infusion in both solid and liquid tumor patients.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1177\/10781552241291221","type":"journal-article","created":{"date-parts":[[2024,10,22]],"date-time":"2024-10-22T03:00:37Z","timestamp":1729566037000},"page":"454-458","update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":0,"title":["Decreasing IV magnesium infusion time to improve delivery of patient care"],"prefix":"10.1177","volume":"32","author":[{"ORCID":"https:\/\/orcid.org\/0009-0005-4185-2781","authenticated-orcid":false,"given":"Molly","family":"Lofy","sequence":"first","affiliation":[{"name":"Pharmacy, UW Health"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cameron","family":"Ninos","sequence":"additional","affiliation":[{"name":"Pharmacy, UW Health"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elizabeth","family":"Dow-Hillgartner","sequence":"additional","affiliation":[{"name":"Pharmacy, UW Health"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"179","published-online":{"date-parts":[[2024,10,21]]},"reference":[{"key":"e_1_3_2_2_2","doi-asserted-by":"publisher","DOI":"10.5049\/EBP.2007.5.2.126"},{"key":"e_1_3_2_3_2","doi-asserted-by":"publisher","DOI":"10.1053\/ctrv.1999.0097"},{"key":"e_1_3_2_4_2","doi-asserted-by":"publisher","DOI":"10.1093\/ndtplus\/sfr163"},{"key":"e_1_3_2_5_2","doi-asserted-by":"publisher","DOI":"10.2146\/ajhp110574"},{"key":"e_1_3_2_6_2","doi-asserted-by":"publisher","DOI":"10.1007\/s00520-016-3252-9"},{"key":"e_1_3_2_7_2","doi-asserted-by":"publisher","DOI":"10.1007\/s00520-018-4127-z"},{"key":"e_1_3_2_8_2","first-page":"49","article-title":"Evaluation of prolonged magnesium infusion after allogeneic hematopoietic cell transplant","volume":"32","author":"Seago K","year":"2023","unstructured":"Seago K, Goodner JA, Dillaman M, et al. Evaluation of prolonged magnesium infusion after allogeneic hematopoietic cell transplant. Support Care Cancer Off J Multinatl Assoc Support Care Cancer 2023; 32: 49.","journal-title":"Support Care Cancer Off J Multinatl Assoc Support Care Cancer"},{"key":"e_1_3_2_9_2","article-title":"Alternative magnesium sulphate regimens for women with pre-eclampsia and eclampsia","volume":"10","author":"Diaz V","year":"2023","unstructured":"Diaz V, Long Q, Oladapo OT. Alternative magnesium sulphate regimens for women with pre-eclampsia and eclampsia. Cochrane Database Syst Rev 2023; 10: CD007388.","journal-title":"Cochrane Database Syst Rev"},{"key":"e_1_3_2_10_2","unstructured":"DailyMed - MAGNESIUM SULFATE injection solution. Accessed September 16 2024. https:\/\/dailymed.nlm.nih.gov\/dailymed\/drugInfo.cfm?setid=e175d329-315f-4f3b-bb4c-06ad4e042967"},{"key":"e_1_3_2_11_2","unstructured":"Huff C. Here\u2019s a new data point for cancer patients to consider: \u201ctime toxicity\u201d. STAT. April 10 2023. Accessed September 16 2024. https:\/\/www.statnews.com\/2023\/04\/10\/cancer-treatment-end-of-life-time-toxicity\/"},{"key":"e_1_3_2_12_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41408-023-00801-1"},{"key":"e_1_3_2_13_2","doi-asserted-by":"publisher","DOI":"10.1200\/JOP.2015.008417"}],"container-title":["Journal of Oncology Pharmacy Practice"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/10781552241291221","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/10781552241291221","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/10781552241291221","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,2]],"date-time":"2026-05-02T02:30:28Z","timestamp":1777689028000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/10781552241291221"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,10,21]]},"references-count":12,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2026,4]]}},"alternative-id":["10.1177\/10781552241291221"],"URL":"https:\/\/doi.org\/10.1177\/10781552241291221","relation":{},"ISSN":["1078-1552","1477-092X"],"issn-type":[{"value":"1078-1552","type":"print"},{"value":"1477-092X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,10,21]]}}}